Biospyder Technologies Inc

Advanced Bio Matrix is a company based in Carlsbad, CA that specializes in providing a wide range of collagen-based products for various applications, including research, bioprinting, and tissue engineering. Their product offerings include different types of collagen, such as Type I, Type II, and Type III, in various forms like solutions, powders, and bioinks. They also offer collagen-coated plates, scaffolds, and substrates, as well as other components and reagents necessary for bioprinting and 3D hydrogel formation. With a focus on quality and innovation, Advanced Bio Matrix aims to meet the diverse needs of researchers and scientists in the field of regenerative medicine. Their collagen products are derived from bovine, human, and rat sources, providing researchers with a wide range of options to suit their specific requirements. Whether it's for studying cell behavior, developing tissue models, or creating bioprinted constructs, Advanced Bio Matrix offers a comprehensive range of collagen-based solutions to support cutting-edge research and development in the field of regenerative medicine.Generated from the website

Thorp Institute (TI), established in 1995, is a leading authority on advanced microcurrent technologies and serves as an integrative medicine training and therapy center in Encinitas, CA. It is the exclusive global distributor of the Electro-Equiscope technology and provides comprehensive training for health practitioners and technicians. In addition to its educational role, TI operates as a clinical office where patients can experience innovative integrative therapies. The institute is committed to empowering practitioners with protocols aimed at enhancing wellness, pain management, and athletic performance. Generated from the website

Ambit Biosciences Corporation is a biopharmaceutical company based in San Diego, CA, dedicated to the discovery, development, and commercialization of innovative drugs targeting unmet medical needs in oncology, autoimmune, and inflammatory diseases. The company focuses on inhibiting kinases that drive these diseases, with a robust pipeline that includes internally discovered programs aimed at validated kinase targets. The company's lead drug candidate, quizartinib, is a potent and selective FLT3 kinase inhibitor administered once daily, currently in development for treating acute myeloid leukemia (AML). Ambit leverages its kinase expertise to optimize and develop a sustainable pipeline of small molecule kinase inhibitors, positioning itself as a key partner in the field. Generated from the website